EXICURE INC (XCUR) Stock Price, Forecast & Analysis

USA • Nasdaq • NASDAQ:XCUR • US30205M3097

4.31 USD
-0.08 (-1.82%)
Last: Feb 10, 2026, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News

XCUR Key Statistics, Chart & Performance

Key Statistics
Market Cap27.45M
Revenue(TTM)N/A
Net Income(TTM)-9.23M
Shares6.37M
Float2.38M
52 Week High15.91
52 Week Low3.1
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-3.07
PEN/A
Fwd PEN/A
Earnings (Next)03-16
IPO2018-05-09
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
XCUR short term performance overview.The bars show the price performance of XCUR in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 -20 -30

XCUR long term performance overview.The bars show the price performance of XCUR in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 -40

The current stock price of XCUR is 4.31 USD. In the past month the price decreased by -26.2%. In the past year, price decreased by -57.03%.

EXICURE INC / XCUR Daily stock chart

XCUR Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to XCUR. When comparing the yearly performance of all stocks, XCUR is a bad performer in the overall market: 85.09% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating
XCUR Full Technical Analysis Report

XCUR Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to XCUR. XCUR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
XCUR Full Fundamental Analysis Report

XCUR Financial Highlights

Over the last trailing twelve months XCUR reported a non-GAAP Earnings per Share(EPS) of -3.07. The EPS decreased by -35.8% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -60.45%
ROE -133.23%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%32.89%
Sales Q2Q%N/A
EPS 1Y (TTM)-35.8%
Revenue 1Y (TTM)-100%
XCUR financials

XCUR Forecast & Estimates


Analysts
Analysts43.33
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A
XCUR Analyst EstimatesXCUR Analyst Ratings

XCUR Ownership

Ownership
Inst Owners6.15%
Ins Owners0%
Short Float %3.7%
Short Ratio0.1
XCUR Ownership

XCUR Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC15.32393.136B
AMGN AMGEN INC16.18196.357B
GILD GILEAD SCIENCES INC16.51182.665B
VRTX VERTEX PHARMACEUTICALS INC22.73117.594B
REGN REGENERON PHARMACEUTICALS16.2579.341B
ALNY ALNYLAM PHARMACEUTICALS INC48.2142.669B
INSM INSMED INC N/A31.681B
NTRA NATERA INC N/A29.21B
BIIB BIOGEN INC12.4227.736B
UTHR UNITED THERAPEUTICS CORP16.0620.376B

Related stock screener links

View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges

About XCUR

Company Profile

XCUR logo image Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The company is headquartered in Chicago, Illinois and currently employs 7 full-time employees. The company went IPO on 2018-05-09. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The firm is also exploring strategic alternatives to maximize stockholder value.

Company Info

EXICURE INC

2430 N. Halsted St.

Chicago ILLINOIS 60614 US

CEO: David A. Giljohann

Employees: 7

XCUR Company Website

XCUR Investor Relations

Phone: 18476731707

EXICURE INC / XCUR FAQ

Can you describe the business of EXICURE INC?

Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The company is headquartered in Chicago, Illinois and currently employs 7 full-time employees. The company went IPO on 2018-05-09. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The firm is also exploring strategic alternatives to maximize stockholder value.


What is the stock price of EXICURE INC today?

The current stock price of XCUR is 4.31 USD. The price decreased by -1.82% in the last trading session.


Does EXICURE INC pay dividends?

XCUR does not pay a dividend.


What is the ChartMill technical and fundamental rating of XCUR stock?

XCUR has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


Can you provide the PE ratio for XCUR stock?

EXICURE INC (XCUR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.07).


Can you provide the market cap for EXICURE INC?

EXICURE INC (XCUR) has a market capitalization of 27.45M USD. This makes XCUR a Nano Cap stock.


Can you provide the ownership details for XCUR stock?

You can find the ownership structure of EXICURE INC (XCUR) on the Ownership tab.